A. Plowright

发表

Automated De-Novo Design in Medicinal Chemistry: Which Types of Chemistry Does a Generative Neural Network Learn?

C. Grebner, H. Matter, A. Plowright, 2020, Journal of medicinal chemistry.

A protein tertiary structure mimetic modulator of the Hippo signalling pathway

Stéphanie M. Guéret, A. Plowright, Hacer Karatas, 2020, Nature Communications.

Rethinking drug design in the artificial intelligence era

G. Schneider, J. Listgarten, A. Plowright, 2019, Nature Reviews Drug Discovery.

Identification of an anti-MRSA dihydrofolate reductase inhibitor from a diversity-oriented synthesis.

David R Spring, Martin Welch, Warren R J D Galloway, 2008, Chemical communications.

Skeletal diversity construction via a branching synthetic strategy.

Suzanne Fergus, Andreas Bender, David R Spring, 2006, Chemical communications.

New Modalities for Challenging Targets in Drug Discovery.

Herbert Waldmann, Stéphanie M. Guéret, Alleyn T Plowright, 2017, Angewandte Chemie.

Heart regeneration: opportunities and challenges for drug discovery with novel chemical and therapeutic methods or agents.

A. Plowright, O. Engkvist, A. Gill, 2014, Angewandte Chemie.

Oxadiazoles in medicinal chemistry.

Jonas Boström, Anders Hogner, Alleyn T Plowright, 2012, Journal of medicinal chemistry.

Discovery of AZD6642, an inhibitor of 5-lipoxygenase activating protein (FLAP) for the treatment of inflammatory diseases.

Susanne Winiwarter, Johan Ulander, Anna Pettersen, 2015, Journal of medicinal chemistry.

Macrocyclic Modalities Combining Peptide Epitopes and Natural Product Fragments

Stéphanie M. Guéret, A. Plowright, H. Waldmann, 2020, Journal of the American Chemical Society.

Joining Forces: The Chemical Biology-Medicinal Chemistry Continuum.

A. Plowright, C. Ottmann, Y. Auberson, 2017, Cell chemical biology.

Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.

A. Plowright, J. Ulander, J. Jensen, 2013, Journal of medicinal chemistry.

Discovery of retinoic acid receptor agonists as proliferators of cardiac progenitor cells through a phenotypic screening approach

A. Plowright, I. Barrett, S. Martinsson, 2019, Stem cells translational medicine.

Characterisation of de novo mutations in the C-terminal domain of proprotein convertase subtilisin/kexin type 9.

A. Plowright, S. Breuer, S. Geschwindner, 2015, Protein engineering, design & selection : PEDS.

CRISPR‐Knockout Screen Identifies Dmap1 as a Regulator of Chemically Induced Reprogramming and Differentiation of Cardiac Progenitors

A. Plowright, B. Rosen, G. Palano, 2019, Stem cells.

Phenotypic Screen for Cardiac Regeneration Identifies Molecules with Differential Activity in Human Epicardium-Derived Cells versus Cardiac Fibroblasts.

M. Goumans, A. Plowright, O. Engkvist, 2017, ACS chemical biology.

What is the most important approach in current drug discovery: doing the right things or doing things right?

A. Plowright, A. Gill, T. Elebring, 2012, Drug discovery today.

Discovery of the Fibrinolysis Inhibitor AZD6564, Acting via Interference of a Protein-Protein Interaction.

W. Lindberg, A. Plowright, Yafeng Xue, 2014, ACS medicinal chemistry letters.

Discovery of a series of indan carboxylic acid glycogen phosphorylase inhibitors.

A. Plowright, N. Selmi, P. Kenny, 2010, Bioorganic & medicinal chemistry letters.

Phenotypic screen identifies FOXO inhibitor to counteract maturation and promote expansion of human iPS cell-derived cardiomyocytes.

A. Plowright, D. Schade, B. Greber, 2022, Bioorganic & medicinal chemistry.

Cyclic peptide production using a macrocyclase with enhanced substrate promiscuity and relaxed recognition determinants.

Wael E Houssen, A. Plowright, K. Sivonen, 2017, Chemical communications.

Triantennary GalNAc Molecular Imaging Probes for Monitoring Hepatocyte Function in a Rat Model of Nonalcoholic Steatohepatitis

A. Plowright, H. Schreuder, A. Kannt, 2020, Advanced science.

Synthesis and evaluation of bishydroquinone derivatives of (-)-saframycin A: identification of a versatile molecular template imparting potent antiproliferative activity.

A. Plowright, A. Myers, 2001, Journal of the American Chemical Society.

Toward Second‐Generation Cardiomyogenic and Anti‐cardiofibrotic 1,4‐Dihydropyridine‐Class TGFβ Inhibitors

Tessa R Werner, A. Plowright, D. Schade, 2019, ChemMedChem.

Skeletal diversity construction via a branching synthetic strategy.

Suzanne Fergus, Andreas Bender, Warren R. J. D. Galloway, 2006, Chemical communications.

Late-Stage Functionalization with Cysteine Staples Generates Potent and Selective Melanocortin Receptor-1 Agonists.

Andrew M. White, A. Plowright, D. Craik, 2022, Journal of medicinal chemistry.

Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes.

Andrew G. Leach, A. Plowright, Robert D. M. Davies, 2012, Bioorganic & medicinal chemistry letters.

Total synthesis of (+)-phorboxazole A, a potent cytostatic agent from the sponge Phorbas sp.

A. Plowright, T. Ye, G. Pattenden, 2003, Organic & biomolecular chemistry.

Synthetic studies towards phorboxazole A. A convergent synthesis of the C31C46 polyene oxane-hemiacetal side chain

A. Plowright, T. Ye, G. Pattenden, 1998 .

Medicinal Chemistry Approaches to Heart Regeneration.

A. Plowright, D. Schade, 2015, Journal of medicinal chemistry.

Synthetic studies towards phorboxazole A. Stereoselective synthesis of the C3–C19 bis-oxane oxazole portion of the phorboxazole macrolide

A. Plowright, G. Pattenden, 2000 .

Transcriptional response pathways in a yeast strain sensitive to saframycin a and a more potent analog: evidence for a common basis of activity.

S. Schaus, A. Plowright, A. Myers, 2002, Chemistry & biology.

Functional screening in human cardiac organoids reveals a metabolic mechanism for cardiomyocyte cell cycle arrest

David E James, Benjamin L Parker, James E Hudson, 2017, Proceedings of the National Academy of Sciences.

A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.

David Buttar, S. Steinbacher, A. Plowright, 2010, Bioorganic & medicinal chemistry.

Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease.

A. Plowright, J. Ulander, Malin Lemurell, 2019, Journal of medicinal chemistry.

Directing evolution: the next revolution in drug discovery?

Andrew M. Davis, Eric Valeur, Alleyn T. Plowright, 2017, Nature Reviews Drug Discovery.

Hypothesis driven drug design: improving quality and effectiveness of the design-make-test-analyse cycle.

R. A. Thompson, Jonas Pettersson, Jan Kihlberg, 2012, Drug discovery today.

Development of Novel Melanocortin Receptor Agonists Based on the Cyclic Peptide Framework of Sunflower Trypsin Inhibitor-1.

Philipp M. Cromm, A. Plowright, D. Craik, 2018, Journal of medicinal chemistry.

Drug Screening in Human PSC-Cardiac Organoids Identifies Pro-proliferative Compounds Acting via the Mevalonate Pathway.

A. Plowright, D. James, D. Elliott, 2019, Cell stem cell.

Emerging modes-of-action in drug discovery.

Eric Valeur, Frank Narjes, Christian Ottmann, 2019, MedChemComm.

Aligned nanofiber scaffolds improve functionality of cardiomyocytes differentiated from human induced pluripotent stem cell-derived cardiac progenitor cells

A. Plowright, A. Sabirsh, S. Martinsson, 2020, Scientific Reports.

High-content phenotypic assay for proliferation of human iPSC-derived cardiomyocytes identifies L-type calcium channels as targets.

A. Plowright, S. Bekiranov, I. Barrett, 2019, Journal of molecular and cellular cardiology.

Long-term self-renewing human epicardial cells generated from pluripotent stem cells under defined xeno-free conditions

Sean P. Palecek, M. Goumans, A. Plowright, 2016, Nature Biomedical Engineering.

Human Induced Pluripotent Stem Cell‐Derived Cardiac Progenitor Cells in Phenotypic Screening: A Transforming Growth Factor‐β Type 1 Receptor Kinase Inhibitor Induces Efficient Cardiac Differentiation

Chad H. Koonce, A. Plowright, S. Kattman, 2015, Stem cells translational medicine.

Melanocortin 1 Receptor Agonists Based on a Bivalent, Bicyclic Peptide Framework.

Andrew M. White, A. Plowright, D. Craik, 2021, Journal of medicinal chemistry.

Design of small molecule inhibitors of acetyl-CoA carboxylase 1 and 2 showing reduction of hepatic malonyl-CoA levels in vivo in obese Zucker rats.

A. Plowright, Tobias Noeske, V. Schnecke, 2011, Bioorganic & medicinal chemistry.

Design and synthesis of a novel series of cyclohexyloxy-pyridyl derivatives as inhibitors of diacylglycerol acyl transferase 1

Andrew G. Leach, A. Plowright, M. Waring, 2013 .

Comparative transcriptomic analysis identifies genes differentially expressed in human epicardial progenitors and hiPSC-derived cardiac progenitors.

M. Goumans, A. Plowright, A. G. Gittenberger-de Groot, 2016, Physiological genomics.

Unique photoaffinity probes to study TGFβ signaling and receptor fates.

A. Plowright, D. Schade, F. Wesseler, 2019, Chemical communications.

Oxadiazoles in medicinal chemistry.

A. Plowright, Jonas Boström, A. Hogner, 2012, Journal of medicinal chemistry.

C−H Functionalization—Prediction of Selectivity in Iridium(I)‐Catalyzed Hydrogen Isotope Exchange Competition Reactions

A. Plowright, V. Derdau, S. Güssregen, 2020, Angewandte Chemie.